NCAPD2

Across TCGA pan-cancer cohorts, NCAPD2 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated NCAPD2 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher NCAPD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NCAPD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, LUAD, and SARC are the cancer types where NCAPD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.112	0.664	.020	12	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	12	view →
SARC	DFS	Median	All	0.179	0.612	.024	6	view →
LIHC	DFS	Median	All	0.096	0.553	.030	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ACC	DFS	Median	All	0.209	0.659	.027	3	view →
STAD	OS	Median	III,IV	0.166	0.512	.027	3	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →
UCEC	OS	Median	II,III,IV	0.877	0.459	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

NCAPD2–LUSC (OS)

Open the LUSC breakdown →